Skip to content
lifestyle.hoteleguide.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Capricor Therapeutics
Capricor Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
November 10, 2026
Capricor’s HOPE-3 Phase 3 Cardiac Results for Deramiocel Win American Heart Association Outstanding Research Award in Pediatric Cardiology
November 9, 2026
Capricor Therapeutics to Report Third Quarter 2026 Financial Results and Provide Recent Corporate Update on November 10
November 3, 2026
Capricor Therapeutics Presents Positive HOPE-3 Open-Label Extension Data on Upper Limb Function in Duchenne Muscular Dystrophy at 2026 World Muscle Society Congress
October 5, 2026
Capricor Therapeutics to Present HOPE-3 and HOPE-3 Open-Label Extension Data at 2026 World Muscle Society Congress
September 17, 2026
Capricor Therapeutics Announces Extension of PDUFA Target Action Date as FDA Continues Review of Deramiocel BLA
August 24, 2026
Capricor Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 13, 2026
Capricor Therapeutics to Report Second Quarter 2026 Financial Results and Provide Recent Corporate Update on August 13
August 10, 2026
Capricor Therapeutics Provides Update on FDA Advisory Committee Meeting for Deramiocel
July 30, 2026
The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy
July 29, 2026
1
2
Next Page
→